Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 173 of the 174 references it cites were found in a registry or an index; 34 of the 178 sources its claims cite were checked for support.

The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials

Open access

Abstract

Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterized by diverse and prominent changes in behavior and personality. One of the greatest challenges in bvFTD is to capture, measure and predict its disease progression, due to clinical, pathological and genetic heterogeneity. Availability of reliable outcome measures is pivotal for future clinical trials and disease monitoring. Detection of change should be objective, clinically meaningful and easily assessed, preferably associated with a biological process. The purpose of this scoping review is to examine the status of longitudinal studies in bvFTD, evaluate current assessment tools and propose potential progression markers. A systematic literature search (in PubMed and Embase.com ) was performed. Literature on disease trajectories and longitudinal validity of frequently-used measures was organized in five domains: global functioning, behavior, (social) cognition, neuroimaging and fluid biomarkers. Evaluating current longitudinal data, we propose an adaptive battery, combining a set of sensitive clinical, neuroimaging and fluid markers, adjusted for genetic and sporadic variants, for adequate detection of disease progression in bvFTD.

Overview

CoChat Summary

TL;DR

This scoping review of 149 studies concludes that no single measure adequately captures behavioral variant frontotemporal dementia (bvFTD) progression and recommends a multimodal, bvFTD-specific battery adjusted for genetic versus sporadic variants. It identifies FTD-specific clinical scales, social cognition questionnaires, structural/functional neuroimaging, and neurofilament light (NfL) as the most evidence-supported candidate progression markers.

Key findings

  • The search generated 4,931 articles (2,245 PubMed, 2,686 Embase), 2,842 after deduplication, and 149 included articles; evidence was organized into global functioning, behavior, (social) cognition, neuroimaging, and fluid biomarkers.
  • For global functioning and behavior, FTLD-CDR is useful for coarse staging but has low sensitivity; FTD-FRS captures multi-domain deterioration over 1–5 years; FBI and CBI-R were more consistently sensitive to progression in sporadic and genetic bvFTD over 1–4 years than the NPI. DAS and SRI are promising but have limited or lacking follow-up.
  • For cognition and social cognition, ACE-R is a more valid cognitive progression screener with marked decline over 1–5 years, whereas MMSE decline is modest or lacking and unrelated to frontotemporal imaging changes; composite scores increase sensitivity. Social cognition tools such as EK-60, IRI, and RSMS are promising, but longitudinal evidence is limited or inconsistent.
  • For neuroimaging and fluid biomarkers, MRI grey matter atrophy and DTI white matter changes detect progression, with DTI possibly preceding grey matter atrophy; FDG-PET and ASL show metabolic/perfusion changes. NfL in CSF or serum increased over 9–12 months in genetic and sporadic bvFTD and predicted prodromal-to-symptomatic conversion in genetic bvFTD; most other fluid markers still need longitudinal validation. The paper notes that 70% of bvFTD cases are non-genetic, yet leading progression studies, especially neuroimaging, were predominantly in genetic cohorts.

Methods

  • Scoping review conducted according to PRISMA; systematic search in PubMed and Embase.com from inception to September 5, 2022, without date or language restrictions, using terms for “behavioral,” “frontotemporal dementia,” and “longitudinal studies”; duplicates removed with Endnote X20.4 using the Amsterdam Efficient Deduplication method and Bramer-method.
  • Two reviewers screened titles/abstracts and full texts. Inclusion required a bvFTD population and either multiple follow-up measurements or relevant cross-sectional associations with disease progression/severity; exclusions were case reports, animal studies, reviews, and studies focused on topics other than disease progression.
  • Methodological quality was weighed by diagnostic accuracy (probable or definite bvFTD by international criteria), sample size, follow-up time, and appropriateness of outcome measures; findings were narratively synthesized across five prespecified domains, and meta-analysis was not performed.

Limitations

  • Stated: heterogeneous cohorts (genetically undefined versus mutation-specific patients), variable follow-up time, mixed longitudinal and cross-sectional designs, and use of staging instruments less sensitive for bvFTD seriously complicated comparative weighing of results; meta-analysis was therefore not possible.
  • Stated: most large and leading progression studies, particularly neuroimaging studies, were predominantly performed in genetic bvFTD cohorts; sporadic cases are typically diagnosed later, are less well defined, and often rely on clinical diagnosis rather than underlying pathology, so current recommendations rest on fewer validation studies in sporadic bvFTD.
  • Evident: the search ended September 5, 2022, so later literature is not captured; the paper also states that social cognition tools require further longitudinal, preferably cross-cultural validation and improved psychometrics to overcome floor effects.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fnagi.2024.1382593

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart of the search and selection procedure of studies.
Figure 1 Flowchart of the search and selection procedure of studies.CC BY · PubMed Central
Figure 2 Central recommendations for a multi-modal approach and future research in bvFTD. *SRI, Stereotypy Rating Inventory; DAS, Dimensional Apathy Scale; IRI, Interpersonal Reactivity Index; RSMS, Revised Self-Monitoring Scale; NPA, neuropsychological assessment; NIH-EXAMINER, Neurobehavioral Evaluation & Research; sTREM, soluble triggering receptor expressed on myeloid cells 2; GFAP, glial fibrillary acidic protein.
Figure 2 Central recommendations for a multi-modal approach and future research in bvFTD. *SRI, Stereotypy Rating Inventory; DAS, Dimensional Apathy Scale; IRI, Interpersonal Reactivity Index; RSMS, Revised Self-Monitoring Scale; NPA, neuropsychological assessment; NIH-EXAMINER, Neurobehavioral Evaluation & Research; sTREM, soluble triggering receptor expressed on myeloid cells 2; GFAP, glial fibrillary acidic protein.CC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 6 Not valid · 92 Not checked · 26 Own results and interpretations

82 more claims · 11 with their cited sources checked

Create a free account to see all 144 claims and to verify the 140 references still open.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 17
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 174 references

Research works printed but not linked: 2

  1. Aw, 2002, Facial expressions of emotion: stimuli and tests (FEEST)
  2. Malpetti, 2022, Synaptic loss in behavioural variant frontotemporal dementia revealed by [

Cited by

See all 8

Metadata

Authors
Fieldhouse, J. L. P., van Paassen, D. N., van Engelen, M.-P. E., De Boer, S. C. M., Hartog, W. L., Braak, S., Schoonmade, L. J., Schouws, S. N. T. M., Krudop, W. A., Oudega, M. L., Mutsaerts, H. J. M. M., Teunissen, C. E., Vijverberg, E. G. B., & Pijnenburg, Y. A. L.
Affiliations
  • Amsterdam Neuroscience (NL)
  • Vrije Universiteit Amsterdam (NL)
  • GGZ inGeest (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Corresponding author
  • Fieldhouse, Jay L. P.
  • van Paassen, Dirk N.
Venue
Frontiers in Aging Neuroscience
Published
2024-05-09
Volume
16
Pages
1382593-1382593
ISSN
1663-4365 (ISSN-L)
OpenAlex
W4396775414
Cited by
8
References
174
Citations by year
2026: 6 · 2025: 2
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Stichting Dioraphte
  • Alzheimer Nederland
  • Amsterdam Neuroscience
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords
behavioral variant frontotemporal dementia, disease progression, outcome measures, clinical trial design, longitudinal study, disease trajectories, global functioning, behavior, social cognition, neuroimaging biomarkers, fluid biomarkers, genetic heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials. https://app.cochat.ai/papers/10.3389/fnagi.2024.1382593
The paper
Fieldhouse, J. L. P., van Paassen, D. N., van Engelen, M.-P. E., De Boer, S. C. M., Hartog, W. L., Braak, S., Schoonmade, L. J., Schouws, S. N. T. M., Krudop, W. A., Oudega, M. L., Mutsaerts, H. J. M. M., Teunissen, C. E., Vijverberg, E. G. B., & Pijnenburg, Y. A. L. (2024). The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2024.1382593

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.